Progen Ceases Special Protocol Assessment Program in Liver Cancer

Progen Pharmaceuticals has announced that in light of the recent fast track designation awarded to PI-88 for the prevention of tumor recurrence following curative resection of primary liver cancer and in order to commence the Phase III program as rapidly as possible, the company will no longer continue with the special protocol assessment process.
BioSpectrum